PTN Stock Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
Palatin Technologies, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.32|
|52 Week High||US$0.96|
|52 Week Low||US$0.25|
|1 Month Change||18.60%|
|3 Month Change||-10.76%|
|1 Year Change||-28.94%|
|3 Year Change||-64.74%|
|5 Year Change||-17.30%|
|Change since IPO||-99.99%|
Recent News & Updates
|PTN||US Biotechs||US Market|
Return vs Industry: PTN underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: PTN underperformed the US Market which returned -9.6% over the past year.
|PTN Average Weekly Movement||10.1%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PTN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PTN's weekly volatility (10%) has been stable over the past year.
About the Company
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
|PTN fundamental statistics|
Is PTN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTN income statement (TTM)|
|Cost of Revenue||US$17.54m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||-4,280.50%|
How did PTN perform over the long term?See historical performance and comparison